Gestor documental

Internal Dose Assessment of New 177Lu-Radiopharmaceuticals and its Role in Radiation Protection of Patients

Volver Descargar 347,7k [PDF]


  • radiofarmacos
  • pacientes
  • proteccion contra las radiaciones
  • dosis
  • cuotas
  • dosis terapeuticas







ARN (Argentina)


Puerta Yepes, N.; Rojo, A.M.; Gossio, S.; Crudo, J.L


1 of 10


This article reviews the internal dose assessment of new therapeutic radiopharmaceuticals,

based on Lutetium-177 locally produced, made by the Internal Dosimetry Laboratory (LDI) of the Argentine Nuclear Regulatory Authority. Currently, the study of these radiopharmaceuticals has an increased interest thanks to their potential as an alternative treatment for various types of cancers. Since 2006, the Basic and Applied Radiopharmacy Division of National Atomic Energy Commission (CNEA) has been conducting studies on the production, labelling, quality control, and NIH mice biodistribution of several radiopharmaceuticals based on 177Lu locally produced, which include: 177Lu-EDTMP, 177Lu- DOTMP, 177Lu-DOTA-Substance P, 177Lu-DOTA-Minigastrine and 177Lu-DTPA-SCN-Rituximab. In order to contribute to ensuring the radiation protection of patients, the Internal Dosimetry Laboratory has been complementing the preclinical study of these new radiopharmaceuticals performing a dose assessment. The internal dose assessment of these radiopharmaceuticals included: the activity biodistribution analysis in NIH mice, the estimation of the absorbed dose in healthy organs of interest using MIRD methodology, the extrapolation of the results obtained in mice to humans, the identification of healthy organs with high risk and the estimation of the maximum activity that can be administered to a patient without exceeding the threshold of radiotoxicity in healthy organs. The dosimetric results discussed in this paper are the background needed to progress into the next stage of clinical trials with these radiopharmaceuticals. It can be observed that internal dosimetry assessment has an important role for ensuring radiation protection in patients, since treatment parameters can be optimized out of the estimation of the maximum activity to be administered to the patient. Better protection of healthy organs

is thus achieved by avoiding exceeding the Maximum Tolerable Activity (MTA). 14th International Congress on the International Radiation Protection Association. Cape Town, Sudáfrica, 9 al 13 de mayo de 2016